Dexamethasone oral solution Rx
Generic Name and Formulations:
Dexamethasone 0.5mg; per 5mL.
Roxane Laboratories, Inc.
Indications for Dexamethasone oral solution:
See literature. Initally 0.75–9mg daily. Intensol: mix with liquid or semi-solid food.
See literature. Initally 0.02–0.3mg/kg/day in 3–4 divided doses. Intensol: mix with liquid or semi-solid food.
Systemic fungal infection. Live vaccination. Ocular herpes simplex. Cerebral malaria.
Strongyloides infestation. Varicella. Vaccinia. Recent MI. Tuberculosis. Latent amebiasis. Hypothyroidism. Cirrhosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Renal insufficiency. Ulcerative colitis. Intestinal anastomoses. Diverticulitis. Peptic ulcer. CHF. Hypertension. Osteoporosis. Diabetes. Myasthenia gravis. Hypoprothrombinemia. Supplement with additional steroids in physiologic stress. Avoid abrupt cessation. Monitor weight, growth, fluid and electrolyte balance. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), ephedrine. May potentiate cyclosporine. May anatgonize anticoagulants (monitor), isoniazid, other CYP3A4 substrates (eg, indinavir, erythromycin). Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Toxic epidermal necrolysis possible with thalidomide. Concomitant indomethacin: may get false-negative on dexamethasone suppression test. May suppress reactions to skin tests.
HPA axis suppression, masks infection, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance, weight gain.
Intensol—30mL (w. dropper)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|